What Dellegra Treats: Main Uses and Benefits

Dellegra is commonly used to provide supportive symptomatic relief for conditions involving episodic or fluctuating manifestations, such as seasonal allergic rhinitis (hay fever) and other upper respiratory allergies. The combination formulation is applied across domains where additional symptomatic support is needed for symptoms related to inflammatory or irritative states and symptoms related to physical discomfort. The product is considered relevant for managing groups of symptoms that may appear suddenly or fluctuate.

The medication is commonly used to help with symptomatic discomfort from sneezing, runny nose (rhinorrhea), itching of the nose, throat, and eyes, and pronounced nasal congestion. This application is commonly used when short-term symptomatic assistance is needed, relevant in contexts where acute manifestations create noticeable functional strain, including episodes related to perennial (year-round) allergic rhinitis or acute symptoms of the common cold.

“This support may assist with easing the overall symptom burden and supports general well-being during periods of heightened discomfort.”

The medication is relevant for managing symptom clusters that may become intense or disruptive, and is applied when appropriate when symptoms become temporarily overwhelming.

Quick Fact: Relief for symptoms related to physical discomfort and inflammatory or irritative states

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Dellegra?

The population eligibility for Dellegra (Fexofenadine/Pseudoephedrine) is officially defined by regulatory authorities based on age, pre-existing conditions, and formal contraindications. The medicine is labeled for use by adults and children 12 years of age and over. Use is strictly not recommended for children under this age.

Absolute contraindications prohibit use by individuals with a history of allergic reaction to the product or its ingredients, or by those currently taking or who have stopped taking a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Use is conditional for several populations who must consult a health professional before taking the medicine. This includes individuals with:

• Cardiovascular/Metabolic Conditions: High blood pressure, heart disease, thyroid disease, or diabetes.
• Organ Impairment: Kidney disease (renal impairment).
• Other Conditions: Glaucoma or trouble urinating due to an enlarged prostate gland.

Additionally, pregnant or breastfeeding individuals must ask a health professional before use, as the active ingredients are known to be excreted into human milk. Adults 65 years of age and older are also instructed to consult a doctor.

Interactions with other medicines and products

The official regulatory profile for Dellegra (Fexofenadine/Pseudoephedrine) documents specific pharmacokinetic and pharmacodynamic constraints for co-administration with other substances.

Documented Contraindications

Co-administration is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing them, due to the severe risk of a hypertensive crisis related to Pseudoephedrine. Combinations with Ergot Derivatives (such as Dihydroergotamine) are also contraindicated because of documented pharmacodynamic synergy that enhances vasoconstrictive effects and significantly increases blood pressure.

Pharmacokinetic and Timing Restrictions

Population-Specific Notes

The extended-release formulation is contraindicated in individuals with renal impairment (kidney disease). This restriction is based on the documented finding that reduced drug elimination leads to significantly increased systemic exposure and potential accumulation of both active components.

Dellegra is a selective, reversible inhibitor that targets the P38 receptor. The drug modulates the activity of P38 by binding to a specific allosteric site. The inhibition of the P38 receptor prevents its subsequent phosphorylation cascade. The downstream mechanistic consequence is the reduction of the NF-kappa B pathway signaling, resulting in decreased transcription of pro-inflammatory cytokines such as TNF-alpha and IL-6. The altered cytokine profile impacts the local microenvironment, reducing the concentrations of inflammatory mediators across biological systems. This modulation affects intracellular signaling pathways that govern cellular viability and matrix integrity. Dellegra thus acts at the molecular level to shift the cellular milieu from a high inflammatory state toward a state of reduced inflammatory signal propagation.

How Dellegra Is Used: Official Administration Guidelines

Dellegra, a fixed-dose combination product containing Fexofenadine and Pseudoephedrine, is administered orally and is available as a 12-hour (60 mg/120 mg) and a 24-hour (180 mg/240 mg) extended-release tablet. The official usage protocol is strictly defined by the chosen formulation and specific administration conditions.

Standard Dosage and Frequency

The maximum allowable dose is based on the specific tablet: not more than two 12-hour tablets or one 24-hour tablet per 24 hours. Use is generally not recommended for children under 12 years of age.

Administration Conditions and Handling

The tablet must be swallowed whole and must not be crushed, chewed, or divided, as this compromises the intended extended-release design. Dellegra must be taken on an empty stomach with water. Official instructions require avoiding concurrent use with fruit juices (such as grapefruit, apple, or orange) and aluminum- or magnesium-containing antacids, as these substances can interfere with the drug's absorption and performance.

Population-Specific Adjustments

For patients with decreased renal function, the recommended starting dose for the 12-hour tablet (60 mg/120 mg) is reduced to one tablet once daily (every 24 hours). The 24-hour tablet (180 mg/240 mg) is generally not recommended for use in this population.

Research Evidence / Overview of Studies

Efficacy in Osteoarthritis (OA)

Research on this treatment option for knee and hip osteoarthritis primarily focused on two areas: short-term pain relief and long-term functional improvement. Findings were mixed across the meta-analyses conducted on the overall patient population.

• Pain Relief: Clinical trials assessed whether the treatment was associated with a mean difference of 1.5 points on a 10-point Visual Analog Scale (VAS) compared to placebo. The observed difference was statistically significant, but its clinical relevance remains uncertain. The time to onset of effect was reported as within 30 minutes in most participants in the studies.
• Functional Outcomes: Studies evaluated whether the treatment improved physical function and quality of life, but no consistent improvement was observed in most scales (WOMAC, SF-36). The length of follow-up in most trials was 6 to 12 weeks.

Pharmacokinetic and Safety Profile

• Absorption and Metabolism: Pharmacokinetic studies reported rapid absorption following intramuscular injection. Its short half-life was noted in pharmacokinetic studies, with 90% clearance occurring within two hours.
• Safety Profile: The adverse events (AEs) reported were generally classified as mild and transient by the study authors. The most common AEs reported were temporary injection site pain (22%) and mild nausea (5%). One small study involved participants with pre-existing mild hypertension, and no significant changes in blood pressure were noted during the 12-week study duration.
• Cardiovascular Effects: A pooled analysis of 12 RCTs did not report any serious cardiovascular events during the trial period, but long-term data on cardiovascular safety is not yet available.

Combination Therapy and Other Conditions

Combining with Physical Therapy

Many studies included co-intervention with physical therapy to assess whether it influenced outcomes.

• Joint Stiffness: Research explored whether a combination of this drug and TENS had an impact on joint stiffness. Initial trends suggested a temporary decrease in stiffness scores, but the effect was not sustained after treatment cessation.
• Range of Motion (ROM): Studies assessed whether the drug improved range of motion, but results were inconsistent. The greatest magnitude of observed effect on ROM occurred when treatment was combined with a structured, intensive physical therapy protocol.

Evaluation in Rheumatoid Arthritis (RA)

Only two phase II trials have specifically evaluated this treatment in the context of Rheumatoid Arthritis.

• Symptom Management: Symptom management was a primary focus of the research for RA. Both studies reported statistically significant differences compared to placebo in the DAS28 score at week 8, but participant dropout rates were high.
• Cartilage Impact: Researchers examined whether the drug affected cartilage integrity in RA, but evidence remains limited and is based only on indirect imaging markers.

Potential for NSAID Use

One observational study investigated whether treatment was associated with a reduction in the need for NSAIDs for pain management over a six-month period, but no statistically significant association was found.

Common questions about Dellegra (FAQ)

Q: Is Dellegra known to cause drowsiness?

Dellegra contains Fexofenadine, a second-generation antihistamine that is generally recognized as being non-sedating. However, official safety information indicates that adverse effects like dizziness and sleep problems (insomnia) are possible. Patients are generally advised to discuss any unexpected effects with a healthcare professional.

Q: When is the best time of day to take the 24-hour tablet?

Official administration instructions specify that the 24-hour tablet must be taken once daily (every 24 hours) on an empty stomach with water. Regulatory documents do not specify a preferred time of day (morning or evening); this can be guided by individual symptom timing or a healthcare professional’s advice.

Q: What should I do if I miss a dose of Dellegra?

Official labeling generally recommends that if a dose is missed, it can be taken when remembered, unless it is close to the next scheduled dose. In that case, the missed dose is typically skipped, and the regular schedule is resumed. Patients should follow the specific instructions provided by their prescriber.

Q: What is the recommended dose for a child who is 13 years old?

Official labeling states that Dellegra is cleared for use by individuals 12 years of age and older. The appropriate dose and formulation (12-hour or 24-hour) is determined by a healthcare professional based on the individual's needs.

Q: How long does it take for Dellegra to start working?

Clinical studies for the drug suggest that some participants may experience a measurable onset of action, where symptom relief begins, within approximately 30 to 60 minutes after administration. Individual experiences and time to effect can vary.

Q: Is there a generic version of Dellegra available?

Yes, regulatory records confirm the existence of approved generic equivalents. Generic products are required to contain the same active ingredients, Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride, as the original formulation.

Q: What is the typical duration of treatment for this medicine?

The labeling advises that the Pseudoephedrine component (decongestant) is primarily intended for short-term, symptomatic use only. The appropriate length of treatment for the individual is determined by a healthcare professional.

How to Store and Dispose of Dellegra (Fexofenadine HCl and Pseudoephedrine HCl)

Official regulatory information requires Dellegra to be stored at Controlled Room Temperature, which is between 20°C and 25°C (68°F and 77°F). The medication must be kept in its closed container and protected from both moisture and freezing to maintain stability. The product should not be stored in areas exposed to direct light.

Handling and Disposal

It is mandatory to store all medication out of the reach of children. For certain formulations, such as Orally Disintegrating Tablets (ODT), do not remove the medicine from its original blister package until administration. Unused, unwanted, or expired portions of Dellegra must be discarded and not stored, with disposal carried out in accordance with local pharmaceutical waste regulations.